PTC Therapeutics receives European marketing authorisation for sepiapterin in phenylketonuria treatment
24 June 2025 - US pharmaceutical company PTC Therapeutics, Inc. (NASDAQ: PTCT) announced on Monday that it has received marketing authorisation from the European Commission for Sephience (sepiapterin)...